[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368722-105":59,"doc-detail-368722-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","granzyme-b-and-melittin-in-cancer-immunotherapy-molecular-mechanisms-and-therapeutic-perspectives-in-head-and-neck-cancers","Granzyme B and melittin in cancer immunotherapy - molecular mechanisms and therapeutic perspectives in head and neck cancers","","Granzyme B and melittin are cytotoxic agents with promising roles in cancer immunotherapy, especially in head and neck squamous cell carcinoma. Granzyme B, secreted by cytotoxic T lymphocytes and NK cells, triggers apoptosis via caspase activation and mitochondrial disruption, with expression linked to both improved prognosis and regulatory T cell–mediated immune suppression. Melittin, derived from bee venom, disrupts cancer membranes, induces oxidative stress, and activates apoptotic pathways, though non-specific toxicity motivates targeted delivery such as nanoparticles and liposomes. The review integrates potential synergy, resistance mechanisms, and implications for future HNSC therapies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/granzyme-b-and-melittin-in-cancer-immunotherapy-molecular-mechanisms-and-therapeutic-perspectives-in-head-and-neck-cancers/368722/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/granzyme-b-and-melittin-in-cancer-immunotherapy-molecular-mechanisms-and-therapeutic-perspectives-in-head-and-neck-cancers/368722.png","ImageObject",300,407,{"name":92,"@type":93},"McQueen","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What role does Granzyme B play in cancer immunotherapy for head and neck cancers?","Question",{"text":113,"@type":114},"Granzyme B from cytotoxic T lymphocytes and NK cells can induce apoptosis through caspase activation and mitochondrial disruption. Its expression in HNSC is linked both to better prognosis and to immune suppression involving regulatory T cells.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does melittin exert anticancer effects, and why is targeted delivery important?",{"text":118,"@type":114},"Melittin disrupts cancer cell membranes, induces oxidative stress, and activates apoptotic pathways. Because its cytotoxicity is non-specific, targeted delivery systems such as nanoparticles and liposomes are discussed as therapeutic solutions.",{"name":120,"@type":111,"acceptedAnswer":121},"What resistance mechanisms are considered for Granzyme B and melittin–based approaches?",{"text":122,"@type":114},"The review discusses resistance mechanisms including granzyme inhibitors (e.g., PI-9), altered membrane dynamics, and G2/M cell cycle arrest that can limit therapy effectiveness.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},368722,1790459309,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},5909890329169,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TYPE Review  \nPUBLISHED 22 July 2025  \nDOI 10.3389/fimmu.2025.1628014  \nOPEN ACCESS  \nEDITED BY  \nItalia Falcone,  \nRegina Elena National Cancer Institute (IRCCS), Italy  \nREVIEWED BY  \nFabio Valenti,  \nIRCCS Regina Elena National Cancer Institute, Italy  \nFederica Ganci,  \nIRCCS Regina Elena National Cancer Institute, Italy  \nBiqiong Ren,  \nThe Second People’s Hospital of Hunan (Hunan Provincial Brain Hospital), China  \n*CORRESPONDENCE  \nPaulina Niedz´wiedzka-Rystwej  \n paulina. niedz´[wiedzka-rystwej@usz.edu.pl](wiedzka-rystwej@usz.edu.pl)[ ](wiedzka-rystwej@usz.edu.pl)†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 13 May 2025  \nACCEPTED 02 July 2025  \nPUBLISHED 22 July 2025  \nCITATION  \nMajchrzak A, Lewandowski F, Hrynkiewicz R, Poniewierska-Baran A, Be˛bnowska D and Niedz´wiedzka-Rystwej P (2025) Granzyme Band melittin in cancer immunotherapy: molecular mechanisms and therapeutic perspectives in head and neck cancers. Front. Immunol. 16:1628014 .  \ndoi: 10.3389/fimmu.2025.1628014  \nCOPYRIGHT  \n© 2025 Majchrzak, Lewandowski, Hrynkiewicz, Poniewierska-Baran, Be˛bnowska and Niedz´wiedzka-Rystwej. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nGranzyme B and melittin in cancer immunotherapy:  \nmolecular mechanisms and therapeutic perspectivesin head and neck cancers  \nAdam Majchrzak 1,2†, Filip Lewandowski 2,3†, Rafał Hrynkiewicz 2,3, Agata Poniewierska-Baran 2,3, Dominika Be˛ bnowska 2,3 and Paulina Nied´zwiedzka-Rystwej 2,3,4*  \n1 Department of Infectious, Tropical Diseases and Immune Deﬁciency, Pomeranian Medical University in Szczecin, Szczecin, Poland, 2Center for Experimental Immunology and Immunobiology of Infectious and Cancer Diseases, University of Szczecin, Szczecin, Poland, 3 Institute of Biology, University of Szczecin, Szczecin, Poland, 4 Regional Centre for Digital Medicine, Pomeranian Medical University in Szczecin, Szczecin, Poland  \nGranzyme B (GZMB) and melittin are potent cytotoxic agents with promising applications in cancer immunotherapy, particularly in head and neck squamous cell carcinoma (HNSC) . GZMB, secreted by cytotoxic T lymphocytes and natural killer (NK) cells, induces apoptosis through caspase activation and mitochondrial disruption. Its expression in HNSC correlates with both improved prognosis and, paradoxically, immune suppression via regulatory T cells. Melittin, a peptide derived from bee venom, exerts anticancer effects by disrupting cancer cell membranes, inducing oxidative stress, and activating apoptotic pathways. While effective, its non-speciﬁc cytotoxicity poses a therapeutic challenge, which is being addressed through targeted delivery systems, such as nanoparticles and liposomes. This review highlights the distinct yet potentially complementary roles of GZMB and melittin in modulating tumor cell death and the tumor microenvironment. We also discuss mechanisms of resistance, including expression of granzyme inhibitors (e. g., PI-9), altered membrane dynamics, and G2/M cell cycle arrest. Combining the speciﬁcity of immune-mediated GZMB action with the broad cytotoxicity of melittin may offer synergistic beneﬁts in future therapies. Understanding these molecules ’ mechanisms provides a foundation for novel immunotherapeutic strategies in the treatment of HNSC and other solid tumor.  \nKEYWORDS  \ngranzyme B, melittin, hNSC, cytotoxicity, NK cells, CTL  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nGranzyme B (GZMB), also known as granzyme b, is a caspase like serine proteolytic enzyme, released from granul","cbCainEPGMehRhqV","https://ap.wps.com/l/cbCainEPGMehRhqV","pdf",1004954,15,"English","# Introduction\n## Granzyme B (GZMB) and cytotoxic granules\n## Melittin: direct cytotoxicity and immunomodulation","[{\"question\":\"What role does Granzyme B play in cancer immunotherapy for head and neck cancers?\",\"answer\":\"Granzyme B from cytotoxic T lymphocytes and NK cells can induce apoptosis through caspase activation and mitochondrial disruption. Its expression in HNSC is linked both to better prognosis and to immune suppression involving regulatory T cells.\"},{\"question\":\"How does melittin exert anticancer effects, and why is targeted delivery important?\",\"answer\":\"Melittin disrupts cancer cell membranes, induces oxidative stress, and activates apoptotic pathways. Because its cytotoxicity is non-specific, targeted delivery systems such as nanoparticles and liposomes are discussed as therapeutic solutions.\"},{\"question\":\"What resistance mechanisms are considered for Granzyme B and melittin–based approaches?\",\"answer\":\"The review discusses resistance mechanisms including granzyme inhibitors (e.g., PI-9), altered membrane dynamics, and G2/M cell cycle arrest that can limit therapy effectiveness.\"}]","Granzyme B and melittin in cancer immunotherapy - molecular mechanisms and therapeutic perspectives in head and neck cancers | PDF",1790178196,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46e7d2208038c07d41537ab9bcfbb4da.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e5be121baaaa2b1c80bdd6fd7bfeaf9.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a09b3060820d0b62db6cbebfaff7dbb0.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/117e7ea78233eb41843cab59e4776369.webp",980,1385]